Now Reading
DCGI Nod for Sanofi-GSK’s Phase 3 Trial of Covid Vax in India

DCGI Nod for Sanofi-GSK’s Phase 3 Trial of Covid Vax in India

The DGCI has approved Sanofi and Glaxo Smith Kline (GSK) to conduct Phase III studies of their corona vaccine in India. The pharma giant, a Covid vaccine candidate in India, announced this on Thursday. The double-blind phase-3 study will involve more than 35,000 volunteers over the age of 18. The main objective of the trial is to prevent corona infection as well as reduce serious illness and asymptomatic infection.

Annapurna Das, Country Head, Sanofi Pasteur India, said in a statement that as India is participating in the Phase III study of Sanofi Pasteur, we would like to start enrolling participants for the study in the country soon. He said, ‘We are anticipating what will be necessary to stop it as the virus develops in the coming months and years. We believe that our Corona Adjuvanted, Recombinant Vaccine can make a significant contribution to the ongoing fight against Corona.

This will happen in two phases. The initial study will examine the efficacy of a vaccine formulation targeting the virus strain (D614). While the second phase will evaluate another formulation targeting the beta version (B1351). Recent scientific evidence suggests that antibodies made against the beta variant may provide broad crossprotection against other more permeable variants. The Phase II trial involved 722 adults aged between 18 and 95 years from the US and Honduras. The test produced a strong immunity in people of all ages.

The Phase III study launch follows the results of the Global Interim Phase 2. As noted, recent scientific evidence suggests that antibodies created against the beta variant may provide broader protection against other more permeable variants, so French pharma company Sanofi and its British peer GSK are aiming for a new one in 2021. Billion doses to be produced.

Indo Thai News Co. Ltd. © 2024  All Rights Reserved.

Scroll To Top